Nyxoah's CFO Exits as Company Reaffirms 2026 Financial Guidance
Event summary
- John Landry, Nyxoah's CFO, will step down on October 2, 2026, to pursue another opportunity.
- Loïc Moreau, President International and former CFO, will serve as interim CFO.
- Nyxoah reaffirms its 2026 financial guidance, expecting worldwide net revenue of €36M–€40M.
- The company anticipates a gross margin of 60%–62% and total operating expenses of €99M–€102M for 2026.
The big picture
Nyxoah's CFO transition comes at a critical juncture as the company navigates its path to profitability. The reaffirmation of financial guidance suggests stability, but leadership changes can introduce operational risks. The medical technology sector is highly competitive, and Nyxoah's ability to maintain its growth trajectory will be closely watched by investors and analysts.
What we're watching
- Leadership Stability
- How the interim CFO arrangement will impact financial strategy and investor confidence.
- Financial Execution
- Whether Nyxoah can meet its reaffirmed 2026 revenue and expense targets amid leadership changes.
- Market Perception
- The pace at which Nyxoah can secure a permanent CFO and stabilize its financial leadership.